Miach Orthopedics Appoints New CFO, Company Director

WESTBOROUGH, Mass.–(BUSINESS WIRE)–Miach Orthopedics, Inc., a privately held company dedicated to the development of bioengineered surgical implants for connective tissue restoration, today announced the arrival of Christopher Joyce as Vice President and Chief Financial Officer, and Kevin Sidow has been appointed to the company’s Board of Directors.

“We are thrilled to welcome Chris, who has impressive experience managing finance and operations for medical device startups, and Kevin, a highly accomplished and well-respected leader in bringing orthopedic products to market,” said Martha Shadan, President and CEO, Miach Orthopedics. “Both Chris and Kevin bring expertise that will benefit Miach during this pivotal period of business growth.”

Miach is launching the Bridge-Enhanced® ACL Restoration (BEAR®) implant in the United States this fall. The BEAR implant is the first medical technology to be clinically demonstrated to heal a patient’s torn anterior cruciate ligament (ACL). It received De Novo approval from the United States Food and Drug Administration in December 2020.

As Chief Financial Officer, Joyce will direct the private company’s financial operations. He brings over 30 years of experience managing all aspects of finance and operations, from building a business to commercialization, to working with three venture capitalist-backed startups and a company. NYSE public. He has raised over $2 billion in public and private debt and capital, including two public offerings and over $200 million in venture funding. Joyce has a proven track record as a partner to the CEO, raising capital; building teams; negotiate agreements; manage accounting, taxation, human resources and legal matters; and building an operational infrastructure. For the past two years, he has served as a consulting CFO for several biotech and medical device startups. Previously, he was part of the founding teams as CFO of FRX Polymers, a materials science company, and two medical device companies, Elemé Medical and Percardia. Joyce began his career at XTRA Corporation, a NYSE company, during his last seven years as Vice Chairman and Treasurer. He received his Masters of Business Administration from Babson College and his Bachelor of Commerce from the University of Massachusetts.

Sidow is a medical device industry veteran with over 35 years of orthopedic experience. He was President and Chief Executive Officer of Moximed, Inc. and St. Francis Medical Technologies Inc. and Global President of DePuy Inc., where he oversaw the global orthopedics, spine, trauma and trauma businesses. Johnson & Johnson sports medicine. He sits on the boards of several venture capital-backed life science companies, as well as non-profit organizations. Sidow earned a bachelor’s degree in accounting from West Virginia University.

About the BEAR® implant

The improved bridge® ACL Restoration (BEAR®) The implant is a proprietary bio-engineered implant used to facilitate healing of torn ACL. Unlike reconstruction, which is the current standard of care, the BEAR implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The BEAR implant acts as a bridge between the two ends of the torn ACL. The surgeon injects a small amount of the patient’s blood into the implant and inserts it between the torn ends of the ACL in a minimally invasive procedure. The combination of the BEAR implant and the patient’s blood allows the body to repair the torn ends of the ACL while maintaining the original attachments of the ACL to the femur and tibia. The BEAR implant is absorbed by the body as the ACL heals.

The BEAR implant received De Novo clearance from the United States Food and Drug Administration in December 2020. It is indicated for mature skeletal patients 14 years of age or older with complete ACL tear, confirmed by MRI. Patients should have an ACL stump attached to the tibia to facilitate the restoration. The BEAR device must be implanted within 50 days of the injury.

About Miach Orthopedics, Inc.

Miach Orthopedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to the development of bioengineered surgical implants for connective tissue restoration. The company’s initial focus is the Bridge-Enhanced® ACL Restoration (BEAR®) implant, which represents a paradigm shift in the treatment of ACL tears, from reconstruction to restoration. BEAR technology was pioneered by Martha Murray, MD, founder of Miach Orthopedics, in the Department of Orthopedic Surgery at Boston Children’s Hospital, with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health . For more information about Miach Orthopedics and its products, visit www.miachortho.com and follow the company on Facebook, Twitter and LinkedIn.